Back

prof. dr. L.J. Bont

prof. dr. L.J. Bont

Full Professor
prof. dr. L.J. Bont
  • Center for Translational Immunology (CTI) Research
  • Infectious Diseases Research 2

Biography

Biography

Louis Bont is a Paediatrician Infectiologist at the Wilhelmina Children’s Hospital in the University Medical Center Utrecht, The Netherlands. He leads the Utrecht RSV Research Group. He is the coordinator of the Interest Group on Respiratory Infections of the European Society of Pediatric Infectious Diseases (ESPID) Research Committee. Dr. Bont is the founder and chairman of ReSViNET, an international RSV Research consortium. He has a strong interest in education of young talented researchers and founded the successful Training of Upcoming Leaders in Pediatric Science (TULIPS) career training program in the Netherlands. Dr. Bont served as advisor of the World Health Organization (WHO), the European Center of Disease Control (ECDC) and the Europarliament.

Louis Bont did his medical training at the Academic Medical Center in Amsterdam (1989-1996). He performed his PhD under the supervision of professor Jan Kimpen and professor Cobi Heijnen at the Wilhelmina Children’s Hospital (1997-2000). He was a post-doc at the Garofalo lab in Galveston, Texas (2000-2001). After returning to Utrecht, he followed the pediatric residency program followed by a pediatric infectious diseases and immunology fellowship. He have led the RSV Research Group since 2003 and became full professor in 2015.

The vision of his research is to combine clinical and basic research to decrease the global burden of RSV infection. The mission of his research group is to improve knowledge of RSV epidemiology, and to develop safe and effective therapeutic and preventive interventions.

In his work collaborate with patients is of highest importance. His work is supported by the RSV Patient Advisory Board (PAB) since 2012. The PAB has reviewed every grant application by the RSV Research Group. PAB members have been interviewed for newspapers and national television on RSV-related subjects.

Louis Bont actively participates as a teacher in the SUMMA program. In addition, he founded the TULIPS program in 2008 to train colleagues and young clinician-scientists.

Since April 1st 2021, Louis has been given a new position as medical scientific division manager of the Children's Division of the Wilhelmina Children's Hospital in Utrecht.

Side Activities

Sideactivities. Payment are always to UMC Utrecht

A. related to RSV infection

Advisory boards, consultancy and steering committees

  • GlaxoSmithKline, Advisory Board (from 2020 onwards), (>€2200.-)
  • Janssen, Global virtual advisory board, (from 2021 onwards), (>€2200.-)
  • Julius Clinical, Advisor research, (from 2021 onwards) (>€2200.-)
  • AstraZeneca, (2019 onward), (>€2200)
  • MSD, Advisory Board, (from 2020 onwards) (>€2200.-)
  • Pfizer (from 2021 onwards), (>€2200.-)
  • Sanofi (from 2020 onwards), (>€2200.-)
  • ESCMID, member executive committee member ESCMID Study Group for Respiratory viruses (from 2022 onwards), (no payment)

Meetings, speaker’s fees, chairing

  • AstraZeneca, (2021 onwards, >€2200.-)        
  • AstraZeneca, Global Synagis filmed interview, (2021), (<€2200.-)
  • GlaxoSmithKline, Virtual meeting, Consultancy, (2021), (<€2200.-)
  • Janssen, speaker (2021), (<€2200.-)
  • Merck Sharp & Dome, Speaker, (2021), (<€2200.-)
  • Merck Sharp & Dome, RSV Passive Approaches and Niche SIE, (2021), (<€2200.-)
  • Merck Sharp & Dome, RSV Airways Hyper-reactivity and Asthma, (2021), (<€2200.-) 
  • Merck Sharp & Dome, (Teleconference) Meetings SAC, (2020-2021), (<€2200.-)
  • Sanofi, RSV Medical Education Meeting with experts, (2021), (<€2200.-) 
  • Sanofi, ReSiNET Symposium, (2021), (>€2200.-)

B. Sideactivities not related to RSV infection

  • AstraZeneca,  Consultant asthma, (2021), (<€2200.-)
  • GSK, Data Safety Monitoring Board VZV vaccine, (2020) (>€2200.-)
  • MediRisk, Expert Consultancy/Advisory, (2019), (<€2200.-)
  • MeMed, Review KOL report, (2021) (>€2200.-)
  • ESGREV executive committee (2022), (no payment)

 

Potential Conflicts of Interest

Dr. Bont has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (>€100,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, AstraZeneca, Sanofi, Janssen, Pfizer, MSD and MeMed Diagnostics. UMCU has received major funding for the RSV GOLD study from the Bill and Melinda Gates Foundation. UMCU has received major funding as part of the public private partnership IMI-funded RESCEU and PROMISE projects with partners GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in clinical studies sponsored by MedImmune and Pfizer. UMCU received minor funding (€1,000-25,000 per industrial partner) for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, GSK, Novavax, Pfizer, Moderna, Astrazeneca, MSD, Sanofi, Janssen. Dr. Bont is the founding chairman of the ReSViNET Foundation.

Since April 1st 2021, Louis has been given a new position as medical scientific division manager of the Children's Division of the Wilhelmina Children's Hospital in Utrecht.

Fellowship and Awards

Full Professor (“Stimuleringshoogleraarschap”), expected in May 2015

International Congress of Pediatric Pulmunology (CIPP) Award for Contribution to Understanding Childhood Respiratory Disease and Global Medical Education (2013)

Dirkzwager-Assink Fonds Award by Catharijne Stichting for research on RSV bronchiolitis (2010)

Ter Meulen Fonds lecture: It is not all asthma that wheezes. 27e Congres Nederlandse Vereniging voor Kindergeneeskunde, Veldhoven (2005)

ESPID Fellowship Award 2001 Immunopathogenetic mechanisms of RSV infection in the mouse model (2001)

Royal Dutch Academy of Science (Ter Meulen Fonds Stipendium). Immunopathogenetic mechanisms of RSV infection in the mouse model (2000)

Research Output (275)

Differential isoform expression of Allergin-1 during acute and chronic inflammation

Geerdink Ruben J., Pascoal Ramos Maria Inês, van den Hoogen Luuk L., Radstake Timothy R.D.J., Shibayama Shiro, Shibuya Akira, Bont Louis, Meyaard Linde Dec 2022, In: Immunity, inflammation and disease. 10 , p. 1-9

Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes

Phijffer Emily, de Bruin Odette, Wildenbeest Joanne G., Bont Louis J., Sturkenboom Miriam C.J.M., Van der Maas Nicoline A.T., Ahmadizar Fariba, Bloemenkamp Kitty W.M. 21 Oct 2022, In: Cochrane Database of Systematic Reviews. 2022

Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic

de Hoog Marieke L.A., Sluiter-Post Judith G.C., Westerhof Ilse, Fourie Elandri, Heuvelman Valerie D., Boom Trisja T., Euser Sjoerd M., Badoux Paul, Reusken Chantal, Bont Louis J., Sanders Elisabeth A.M., Jaddoe Vincent W.V., Herpers Bjorn L., Eggink Dirk, Wildenbeest Joanne G., Duijts Liesbeth, van Houten Marlies A., Bruijning-Verhagen Patricia C.J.L. 20 Oct 2022, In: JAMA network open. 5

International changes in respiratory syncytial virus (RSV) epidemiology during the COVID-19 pandemic:Association with school closures

Billard Marie Noëlle, van de Ven Peter M., Baraldi Bianca, Kragten-Tabatabaie Leyla, Bont Louis J., Wildenbeest Joanne G. Sep 2022, In: Influenza and Other Respiratory Viruses. 16 , p. 926-936 11 p.

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Streng Bianca M.M., Bont Marin, Delemarre Eveline M., Binnendijk Rob S., Smit Gaby, den Hartog Gerco, Coppus Antonia M.W., de Vries Esther, Weijerman Michel E., Lamberts Regina, de Graaf Gert, van der Klis Fiona R., Vidarsson Gestur, Rave Neele, Bont Louis J., Wildenbeest Joanne G. 15 Aug 2022, In: The Journal of infectious diseases. 226 , p. 673-677 5 p.

The assessment of future RSV immunizations:How to protect all infants?

Bont Louis, Weil Olivier Catherine, Herting Egbert, Esposito Susanna, Navarro Alonso Jose Antonio, Lega Federico, Mader Silke, Morioka Ichiro, Shen Kunling, Syrogiannopoulos George A., Faust Saul N., Bozzola Elena 9 Aug 2022, In: Frontiers in Pediatrics. 10 , p. 1-7

Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies:Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children

Li Xiao, Bilcke Joke, Vázquez Fernández Liliana, Bont Louis, Willem Lander, Wisløff Torbjørn, Jit Mark, Beutels Philippe, 1 Aug 2022, In: The Journal of infectious diseases. 226 , p. S95-S101

Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection

McGinley Joseph P., Lin Gu Lung, Öner Deniz, Golubchik Tanya, O'Connor Daniel, Snape Matthew D., Gruselle Olivier, Langedijk Annefleur C., Wildenbeest Joanne, Openshaw Peter, Nair Harish, Aerssens Jeroen, Bont Louis, Martinón-Torres Federico, Drysdale Simon B., Pollard Andrew J., 1 Aug 2022, In: The Journal of infectious diseases. 226 , p. S45-S54

Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults

Mao Zhuxin, Li Xiao, Korsten Koos, Bont Louis, Butler Christopher, Wildenbeest Joanne, Coenen Samuel, Hens Niel, Bilcke Joke, Beutels Philippe, 1 Aug 2022, In: The Journal of infectious diseases. 226 , p. S87-S94

SOCIAL LISTENING AND GOOGLE TRENDS AS TOOLS FOR ESTIMATING PUBLIC AWARENESS OF RESPIRATORY SYNCYTIAL VIRUS

Schuurman Gillian Samantha, Bont Louis Jul 2022, In: Pediatric Infectious Disease Journal. 41 , p. e292-e295

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet